Study highlights impact of body fat, blood pressure on heart health in DMD
Modifiable cardiovascular risk factors are associated with adverse changes in the heart muscle of DMD patients.
Modifiable cardiovascular risk factors are associated with adverse changes in the heart muscle of DMD patients.
Orthopedic surgery in patients with DMD should be performed within the first year after initial gait loss for a higher chance of success.
SAT-3247, an investigational oral therapy targeting muscle regeneration in DMD, improved grip strength in a small clinical trial.
The use of corticosteroid treatment could delay respiratory failure in patients with Duchenne muscular dystrophy (DMD).
KER-065, an experimental Duchenne muscular dystrophy (DMD) drug, has been granted Orphan Drug designation by the FDA.
DYNE-251, developed by Dyne Therapeutics and aimed at treating DMD, has received a Breakthrough Therapy Designation.
A recent case report examines the rare case of a teenage girl with DMD that was complicated by acute respiratory distress syndrome.
Sarepta Therapeutics has announced that it will voluntarily stop all shipments of the DMD therapeutic agent Elevidys.
Beta-blocker therapy appears to be beneficial in the context of Duchenne muscular dystrophy (DMD) complicated by cardiac dysfunction.
Accommodating the functional impairments associated with DMD appears to involve substantial costs for households.